Abstract
The role of inflammation in the development and progression of cardiovascular diseases is well established. Systemic inflammation and immune system play a central role in atherogenesis. The strong dependence of the atherosclerotic process on both a state of continuous low grade inflammation and the presence of lipid abnormalities gave impetus to research the association between hyperlipidemia and inflammatory status. In experimental and clinical studies, several inflammatory markers such as C-reactive protein, tumor necrosis factor-alpha, interleukin 6, nuclear factor kappa-β, adhesion molecules, serum amyloid-α, lipoprotein-associated phospholipase A2, fibrinogen and sCD40 ligand are associated with lipids level. Although, cholesterol lowering treatment has several important beneficial effects, there is still little clinical experience or data from clinical trials, in order to treat patients with hyperlipidemia and impaired inflammatory status.
Keywords: Hyperlipidemia, inflammatory markers, cholesterol, lipids, triglycerides, inflammation, atherogenesis, C-Reactive Protein (CRP), TNF-α, nicotinic acid
Current Pharmaceutical Design
Title: Inflammatory Markers in Hyperlipidemia: From Experimental Models to Clinical Practice
Volume: 17 Issue: 37
Author(s): Gerasimos Siasos, Dimitris Tousoulis, Evangelos Oikonomou, Marina Zaromitidou, Christodoulos Stefanadis and Athanasios G. Papavassiliou
Affiliation:
Keywords: Hyperlipidemia, inflammatory markers, cholesterol, lipids, triglycerides, inflammation, atherogenesis, C-Reactive Protein (CRP), TNF-α, nicotinic acid
Abstract: The role of inflammation in the development and progression of cardiovascular diseases is well established. Systemic inflammation and immune system play a central role in atherogenesis. The strong dependence of the atherosclerotic process on both a state of continuous low grade inflammation and the presence of lipid abnormalities gave impetus to research the association between hyperlipidemia and inflammatory status. In experimental and clinical studies, several inflammatory markers such as C-reactive protein, tumor necrosis factor-alpha, interleukin 6, nuclear factor kappa-β, adhesion molecules, serum amyloid-α, lipoprotein-associated phospholipase A2, fibrinogen and sCD40 ligand are associated with lipids level. Although, cholesterol lowering treatment has several important beneficial effects, there is still little clinical experience or data from clinical trials, in order to treat patients with hyperlipidemia and impaired inflammatory status.
Export Options
About this article
Cite this article as:
Siasos Gerasimos, Tousoulis Dimitris, Oikonomou Evangelos, Zaromitidou Marina, Stefanadis Christodoulos and G. Papavassiliou Athanasios, Inflammatory Markers in Hyperlipidemia: From Experimental Models to Clinical Practice, Current Pharmaceutical Design 2011; 17 (37) . https://dx.doi.org/10.2174/138161211798764780
DOI https://dx.doi.org/10.2174/138161211798764780 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Role of the Endothelium in Premature Atherosclerosis: Molecular Mechanisms
Current Medicinal Chemistry Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: Pathogenesis and Treatment Options
Current Vascular Pharmacology Sympathetic Activation in Hypertension and in Hypertension-Related Metabolic Disease
Current Hypertension Reviews Potential Biomarkers for Depression Associated with Coronary Artery Disease: A Critical Review
Current Molecular Medicine Current Developments of Coumarin Compounds in Medicinal Chemistry
Current Pharmaceutical Design Editorial (Hot Topic:Current Situation at Perioperative of Cardiovascular Disease Patients: New Addressing and Perioperative Optimization Techniques)
Current Pharmaceutical Design The Role and Impact of SNPs in Pharmacogenomics and Personalized Medicine
Current Drug Metabolism Post-cardiac Arrest Syndrome in Children
Current Pediatric Reviews Crosstalk Signalling Role in Modulation of Drugs Side Effects
Current Molecular Pharmacology Closed-loop Neuropharmacology for Epilepsy: Distant Dream or Future Reality?
Current Neuropharmacology Editorial [Bioengineering and Clinical Perspectives in Diagnostic and Therapeutic Applications of Microbubbles (Executive Guest Editor: Theodore G. Papaioannou)]
Current Pharmaceutical Design Evaluation of Blood Pressure Control using a New Arterial Stiffness Parameter, Cardio-ankle Vascular Index (CAVI)
Current Hypertension Reviews Clinical Relevance of Postprandial Lipaemia
Current Medicinal Chemistry Imidazoline Receptor Agonists for Managing Hypertension May Hold Promise for Treatment of Intracerebral Hemorrhage
Current Molecular Medicine The Potential Roles of Gamma-Glutamyltransferase Activity in the Progression of Atherosclerosis and Cardiovascular Diseases
Vascular Disease Prevention (Discontinued) Collateral Circulation in Chronic Total Occlusions – an interventional perspective
Current Cardiology Reviews Lagenaria siceraria: A Potential Source of Anti-Hyperlipidemic and Other Pharmacological Agents
Current Nutrition & Food Science Association Between Chlamydia pneumoniae Antibodies and Lung Cancer: A Meta-Analysis
Current Respiratory Medicine Reviews Integrins in Pulmonary Inflammatory Diseases
Current Pharmaceutical Design Fad Diets: Dietary Dilemmas, Predicaments, and Recommendations for its Use
Current Nutrition & Food Science